Any current/future new fundraising through debt or equity?

The company is not planning any new debt currently and intends to fund expansions using internal cash flows and IPO proceeds. Existing debt is minimal, around ₹4.5 crore term loan, with a debt-equity ratio around 0.6. The company aims to remain debt-free in the long term. Planned ₹700 ton capacity expansion will be funded through internal accruals without external borrowing. For inorganic acquisitions, the company may consider term loans but expects to maintain a debt-equity ratio below 1. No mention of new equity fundraising; focus is on organic growth and strategic acquisitions funded by exi

Any current/future capex/capital investment/strategic investment?

A greenfield facility of 700 metric tons capacity is being set up on adjoining land; commissioning to start within the current quarter, expected to take 16-18 months for completion. Expansion capex for this greenfield facility is funded through IPO proceeds and reserve surplus (31 CR allocated); no external debt or bank loan is planned for this capex. The company is exploring inorganic acquisition opportunities, targeting ready-made units for backward-integrated, non-regulatory KSM and raw materials, to immediately upscale capacity alongside expansion. The inorganic acquisition considered i

Future growth expectations in sales/revenue/volumes?

By FY27, expected revenue after inorganic acquisition: ₹360 - 400 crore (Pages 13, 5) Peak revenue potential with combined three facilities (existing, acquired, expanded) by FY28: ₹520 - 550 crore (Pages 18, 13) Capacity expansion: from current 400 MT to about 1,100 MT after inorganic acquisition and greenfield expansion, aiming for 80-85% utilization (Pages 5, 9, 13) Future total expanded capacity expected to reach around 1,800-1,900 MT by FY28 (Page 13) CDMO commercialization expected by Q3 of next financial year, adding to revenues (Page 20) Export revenue targeted to increase fro

Future growth expectations in earnings/operating earnings/profits/EPS?

The company plans substantial growth by FY27 and FY28 with inorganic acquisitions and capacity expansion (total capacity reaching ~1100 metric tons). Revenue guidance for FY27 post-inorganic acquisition is expected to be INR 360-400 crore, up from INR ~120 crore in FY25. Peak revenue on existing 400 MT plant expected at INR 170-180 crore. EBITDA margins are expected to be sustainable around 25-27%, with potential to maintain above 25% even under price correction due to product mix and operational efficiency. PAT and EBITDA have shown strong growth, with PAT nearly quadrupling YoY in recent qua

Current/ Expected Orderbook/ Pending Orders?

The current order book for the next year stands at approximately ₹380 crore for confirmed orders of registered products. (Page 14) Around 60% of this order book is from exports. (Page 14) The company is managing orders and customer requirements through a combination of current capacity, a planned 700-ton expansion, and an inorganic acquisition to de-risk risks related to capacity constraints. (Pages 6, 16, 20) The 700-ton greenfield expansion is expected to commission within 16 to 18 months. (Pages 6, 20) There is ongoing pilot validation for CDMO projects, expected to complete within the quar

Anlon Healthcare LtdQ2 FY26Pharmaceuticals & Biotechnology

Anlon Healthcare Ltd Q2 FY26 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹25.89P/E: 43.5Market Cap: ₹1.4K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

Order

Yes

Capex

Yes

2 of 5 growth signals are positive.

Full analysis

Revenue guidance

Category 2

By FY27, expected revenue after inorganic acquisition: ₹360 - 400 crore (Pages 13, 5)
Peak revenue potential with combined three facilities (existing, acquired, expanded) by FY28: ₹520 - 550 crore (Pages 18, 13)
Capacity expansion: from current 400 MT to about 1,100 MT after inorganic acquisition and greenfield expansion, aiming for 80-85% utilization (Pages 5, 9, 13)
Future total expanded capacity expected to reach around 1,800-1,900 MT by FY28 (Page 13)
CDMO commercialization expected by Q3 of next financial year, adding to revenues (Page 20)
Export revenue targeted to increase from under 5% to around 30% in current year and 60% in next financial year (Page 10)
Focus on higher-value products to improve overall margins and revenues (Pages 18, 9)
Operational efficiencies and product mix optimization aimed to sustain EBITDA margins above 25% (Page 20)

Margin guidance

Category 3

The company plans substantial growth by FY27 and FY28 with inorganic acquisitions and capacity expansion (total capacity reaching ~1100 metric tons).
Revenue guidance for FY27 post-inorganic acquisition is expected to be INR 360-400 crore, up from INR ~120 crore in FY25.
Peak revenue on existing 400 MT plant expected at INR 170-180 crore.
EBITDA margins are expected to be sustainable around 25-27%, with potential to maintain above 25% even under price correction due to product mix and operational efficiency.
PAT and EBITDA have shown strong growth, with PAT nearly quadrupling YoY in recent quarters.
New CDMO projects expected to commercialize by Q3 FY27, contributing to high-value revenue streams.
Management targets a 30%+ revenue CAGR over the next three years on the back of capacity expansion, regulatory approvals, and global market penetration.
Company aims to remain debt-free, supporting sustainable profit growth through internal accruals.

See what Anlon Healthcare Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

The company is not planning any new debt currently and intends to fund expansions using internal cash flows and IPO proceeds.
Existing debt is minimal, around ₹4.5 crore term loan, with a debt-equity ratio around 0.6.
The company aims to remain debt-free in the long term.
Planned ₹700 ton capacity expansion will be funded through internal accruals without external borrowing.
For inorganic acquisitions, the company may consider term loans but expects to maintain a debt-equity ratio below 1.
No mention of new equity fundraising; focus is on organic growth and strategic acquisitions funded by existing reserves.

Order book

Yes

The current order book for the next year stands at approximately ₹380 crore for confirmed orders of registered products. (Page 14)
Around 60% of this order book is from exports. (Page 14)
The company is managing orders and customer requirements through a combination of current capacity, a planned 700-ton expansion, and an inorganic acquisition to de-risk risks related to capacity constraints. (Pages 6, 16, 20)
The 700-ton greenfield expansion is expected to commission within 16 to 18 months. (Pages 6, 20)
There is ongoing pilot validation for CDMO projects, expected to complete within the quarter, with commercialization targeted by Q3 of the next financial year. (Page 20)

See what Anlon Healthcare Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

A greenfield facility of 700 metric tons capacity is being set up on adjoining land; commissioning to start within the current quarter, expected to take 16-18 months for completion.
Expansion capex for this greenfield facility is funded through IPO proceeds and reserve surplus (31 CR allocated); no external debt or bank loan is planned for this capex.
The company is exploring inorganic acquisition opportunities, targeting ready-made units for backward-integrated, non-regulatory KSM and raw materials, to immediately upscale capacity alongside expansion.
The inorganic acquisition considered is about 50-55 CR in size, offering over 1,100 metric tons capacity and expected peak revenue potential around 300 CR.
The combined capacity post-expansion and acquisition is expected to support peak revenues of 360-400 CR.
The company aims to remain debt-free by end of next financial year, funding expansions via internal cash flows.

Track Anlon Healthcare Ltd — get its next earnings analysis in your feed

How does Anlon Healthcare Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisAnlon Healthcare Ltd

Rev 2Mar 3

See where Anlon Healthcare Ltd sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Anlon Healthcare Ltd rank in Pharmaceuticals & Biotechnology?

Compare Anlon Healthcare Ltd against every Pharmaceuticals & Biotechnology company (Q2 FY26) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Anlon Healthcare Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Accretion Pharmaceuticals Ltd (Q2 FY27)
25.85% increase) . Key results statement takeaways from Accretion Pharmaceuticals Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
Sigachi Industries Ltd (Q2 FY27)
Year-on-Year (YoY) Revenue Growth: 18.09% (Q2 FY27 vs Q2 FY26) . Key investor presentation takeaways from Sigachi Industries Ltd's Q2 FY27 investor presentation
Advanced Enzyme Technologies Ltd (Q2 FY27)
Q2 FY27 revenue from operations: ₹2,145 million, up 16% YoY from ₹1,845 million in Q2 FY26 (Page 13, 5). Key investor presentation takeaways from Advanced Enzym
IOL Chemicals (Q2 FY27)
Q2 FY27 revenue from operations: ₹795.0 Cr, a 40.1% year-on-year (YoY) increase from ₹567.5 Cr in Q2 FY26 (Page 7). Key investor presentation takeaways from IOL

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →